A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome

Despite the wide spectrum of experimental compounds tested in clinical trials, there is still no proven pharmacological treatment available for Fragile-X syndrome (FXS), since several targeted clinical trials with high expectations of success have failed to demostrate significant improvements. Here we tested epigallocatechin-3-gallate (EGCG) as a treatment option for ameliorating core cognitive and behavioral features in FXS.

Source: Clinical Nutrition - March 24, 2019 Category: Nutrition Authors: Rafael de la Torre, Susana de Sola, Mag í Farré, Laura Xicota, Aida Cuenca-Royo, Joan Rodriguez, Alba León, Klaus Langohr, María Gomis-González, Gimena Hernandez, Susanna Esteba, Laura del Hoyo, Judit Sánchez-Gutiérrez, Maria José Cortés, Andrés Tags: Randomized Control Trials Source Type: research